Lens epithelium-derived growth factor (LEDGF/p75) is an epigenetic reader and attractive therapeutic target involved in HIV integration and the development of mixed lineage leukaemia (MLL1) fusion-driven leukaemia. Besides HIV integrase and the MLL1-menin complex, LEDGF/p75 interacts with various cellular proteins via its integrase binding domain (IBD). Here we present structural characterization of IBD interactions with transcriptional repressor JPO2 and domesticated transposase PogZ, and show that the PogZ interaction is nearly identical to the interaction of LEDGF/p75 with MLL1. The interaction with the IBD is maintained by an intrinsically disordered IBD-binding motif (IBM) common to all known cellular partners of LEDGF/p75. In addition, based on IBM conservation, we identify and validate IWS1 as a novel LEDGF/p75 interaction partner. Our results also reveal how HIV integrase efficiently displaces cellular binding partners from LEDGF/p75. Finally, the similar binding modes of LEDGF/p75 interaction partners represent a new challenge for the development of selective interaction inhibitors.
Lens epithelium-derived growth factor (LEDGF/p75) is an epigenetic reader recognizing H3K36me3 histone marks via its N-terminal PWWP domain1,2. Knockout of the gene encoding LEDGF/p75 and its splice variant p52 (Psip1) leads to perinatal mortality and severe homeotic skeletal transformations reminiscent of those seen in mice with Hox mutations3. LEDGF/p75 has been linked to Hox gene regulation through its interaction with the mixed lineage leukaemia (MLL1)-menin complex4. Recent work has revealed that LEDGF/p75 is involved in DNA double-strand break (DSB) repair by the homologous recombination repair pathway, through recruitment of C-terminal binding protein interacting protein (CtIP) to DNA DSB5. In addition, LEDGF/p52 has been associated with splicing through its interaction with serine/arginine-rich splicing factor 1 (SRSF1)1,5. Currently it is not clear whether the previously proposed roles of LEDGF/p75 in apoptosis and stress response, as well as its increased expression levels in different cancer types, are related to one of these functions6,7,8,9,10,11.
The Mll gene encodes a histone methyltransferase that forms a ternary complex with LEDGF/p75 and the tumour suppressor menin (MEN1) and is frequently targeted by chromosomal translocations (see ref. 12 for review). Balanced genetic rearrangements result in the formation of new fusion proteins linked to childhood and adult de novo acute leukaemias, as well as therapy-related acute myeloid and lymphoblastic leukaemias. The LEDGF/p75 binding portion of MLL1 is retained in C-terminal fusions (MLLN-fusion), which enables tethering of the MLLN-fusion complexes to MLL1 target genes, resulting in leukaemic transformation. The LEDGF/p75-MLL1-menin complex has been structurally characterized, but the published X-ray data revealed only part of the ternary complex (PDB ID 3U88 (ref. 13)). Recently, we and others identified a second menin-independent MLL1 binding site on LEDGF/p75 (refs 14, 15). Both interfaces were shown to be important for MLL fusion-mediated transformation and represent valuable novel therapeutic targets14,15.
In addition to its cellular function, LEDGF/p75 has been extensively studied in the context of HIV-1 integration16. LEDGF/p75 interacts with HIV integrase (IN) through its C-terminal integrase binding domain (IBD, amino-acid residues 347–429), which is absent in LEDGF/p52 (Fig. 1). This interaction targets viral integration into transcriptionally active regions of the host chromatin recognized by the LEDGF/p75 PWWP domain17,18,19,20,21. The important role of LEDGF/p75 in lentiviral replication triggered the development of small molecules that efficiently block HIV-1 replication, referred to as LEDGINs that target the LEDGF/p75-HIV IN interaction interface22,23,24,25,26,27,28,29. LEDGINs are currently under early clinical development.
Since LEDGF/p75 contributes to optimal viral replication and leukaemic transformation and has become a new potential therapeutic target for drug development, it is crucial to study its physiological interactions. In addition to HIV IN and MLL1-menin, the LEDGF/p75 IBD also interacts with CDC7-activator of S-phase kinase complex (CDC7-ASK), JPO2 (also known as R1, RAM2 and CDCA7L) and pogo transposable element with zinc finger domain (PogZ)30,31,32,33. JPO2 is a 454-amino-acid protein that binds c-Myc via a leucine-zipper motif (amino-acid residues 213–235, Fig. 1) and contributes to c-Myc-mediated transformation in medulloblastoma34. It also acts as a transcriptional repressor of monoamino oxidases A and B by binding to promoter Sp1 elements35,36. PogZ is a domesticated transposase containing a predicted DDE domain at its C-terminus (residues 1,117–1,323; Fig. 1)31. This domain is typically present in enzymes that catalyse DNA cleavage followed by a strand transfer reaction. PogZ regulates the Aurora B kinase through interaction with heterochromatin protein 1, which is required for correct chromosome segregation during mitosis37. Like the HIV pre-integration and MLL1-menin complexes, JPO2 and PogZ are tethered to chromatin by LEDGF/p75 (refs 30, 31, 33).
Despite intensive research focused on HIV IN and MLL1/menin interactions with the LEDGF/p75 IBD, the interaction mode of other physiological IBD-binding partners remained enigmatic. In this work, we characterized the interaction interfaces of both JPO2 and PogZ with the IBD revealing an overlap with the regions responsible for interactions with HIV IN and MLL1. Identification of a highly conserved consensus IBD-binding motif (IBM), present in all validated cellular IBD-interacting proteins, led to discovery of interacts-with-Spt6 (IWS1) as a novel binding partner. Moreover, our results show that the HIV IN interaction site on the IBD overlaps with that of PogZ, JPO2 and MLL1 but shows an alternative interaction mode explaining why HIV IN can efficiently outcompete endogenous interaction partners.
JPO2 interacts with the IBD through a disordered region
To characterize the interactions between the LEDGF/p75 IBD and JPO2, we expressed recombinant protein fragments in E. coli. A JPO2 construct encoding residues 1–130 (JPO21–130), including the specific LEDGF/p75 interaction domain described earlier (amino-acid residues 62–94 (ref. 33) or 77–98 (ref. 30)), was most suitable for overexpression in E. coli (Fig. 1). The IBD construct used in this study contains LEDGF/p75 residues 345–426. The C-terminal boundary was optimized based on analysis of the crystal structure of the IBD in complex with HIV-1 IN (PDB ID 2B4J38). Inclusion of residues N425 and M426 at the C-terminus dramatically improved protein expression yields.
Initially, we characterized the structural features of JPO21–130 in the absence of the IBD. Several lines of evidence led us to conclude that JPO21–130 is intrinsically disordered. In particular, circular dichroism (CD) spectra obtained for the fragment revealed the absence of regular secondary structure elements (Fig. 2a). In addition, evaluation of the protein’s thermal stability in various buffers using differential scanning fluorimetry (DSF) indicated the absence of a hydrophobic core (Fig. 2b). Interestingly, the fluorescence profile of the IBD-JPO21–130 complex suggested formation of a hydrophobic core (Supplementary Fig. 1b). Finally, 1D 1H and two-dimensional (2D) 15N/1H HSQC NMR spectra of JPO21–130 showed poor dispersion of groups of signals that are usually well-dispersed in structured globular proteins (Fig. 2c,d and Supplementary Fig. 2). Our experimental results indicating the lack of a regular JPO21–130 structure are in good agreement with bioinformatic analysis of JPO2 (Supplementary Fig. 1e,f).
The intrinsically disordered JPO21–130 fragment readily interacted with the IBD, forming a stable complex that could be isolated using size-exclusion chromatography (SEC; Supplementary Fig. 1g). The low micromolar binding affinity (Kd=1.9±0.2 μM) of the complex was determined using isothermal titration calorimetry (ITC; Fig. 2f). Interestingly, the stoichiometry of the interaction was estimated as two molecules of IBD per molecule of JPO21–130 (average N=1.9).
PogZ dimers form a stable complex with the IBD
The PogZ fragment used in this study (294 C-terminal residues; PogZ1117–1410) includes the predicted DDE domain, which was previously identified as a region responsible for interaction with the IBD31 (Fig. 1). Domain boundaries were estimated based on secondary structure predictions and sequence homology between the DDE domain of PogZ and Mos1, a transposase with known crystal structure (PDB ID 2F7T39). Biophysical characterization including 1H NMR and 2D 15N/1H HSQC NMR spectra (Fig. 2e and Supplementary Fig. 2) suggested that PogZ1117–1410 adopts a well-defined conformation, although the presence of an unstructured region at the C-terminus (residues 1,373–1,410) was confirmed by limited proteolysis (Supplementary Fig. 3a) and by the presence of more than 30 backbone amide signals in the 2D 15N/1H HSQC spectrum that are considerably sharper and less well-dispersed than the majority of amide signals from the structured part of the protein. The structured character of PogZ1117–1410 was further supported by CD spectra and DSF measurements. In particular, CD spectra revealed a substantial presence of α-helices and β-structures (Fig. 2a) and DSF showed a fluorescence profile typical for a folded protein with a hydrophobic core (Fig. 2b). In addition, PogZ1117–1410 showed a significant increase in thermal stability in the presence of Mg2+, as evidenced by a titration experiment monitored by DSF (Supplementary Fig. 3b). This is in agreement with the known metal-binding properties of the predicted DDE domain in PogZ. To assess the affinity of PogZ1117–1410 for the IBD, we used ITC (Fig. 2g). PogZ1117–1410 binds the IBD with a Kd of 1.6±0.2 μM and a 1:1 stoichiometry (N=0.94). Analytical SEC indicated that PogZ1117–1410 exists as a dimer in solution (Fig. 2h). The retention volume of PogZ1117–1410 (Vr=14.24 ml) corresponded to a molecular weight of 64,600 Da according to the calibration trendline equation. This suggests dimeric assembly of PogZ1117–1410 (theoretical molecular weight: 33,111 Da). Moreover, upon IBD binding the amide group signals from the structured regions of PogZ almost completely disappeared from the triple-resonance three-dimensional (3D) NMR spectra, as the 80 kDa assembly is over the detection limit of these experiments, while only signals from the relatively flexible C-termini can be observed in the spectra. Signals from these flexible regions are proportionally less affected by the molecular weight increase upon complex formation.
Together, these data suggest that PogZ1117–1410 forms a structured dimer with disordered C-termini. As analytical SEC indicated monomeric assembly of free IBD in solution (Supplementary Fig. 3c) and dimeric assembly of free PogZ1117–1410 (Fig. 2h), each PogZ dimer forms a complex with two molecules of IBD.
Interaction interfaces for cellular partners on IBD overlap
We employed NMR spectroscopy for detailed characterization of the interactions of the IBD with JPO2 and PogZ. Overlays of the 2D 15N/1H HSQC spectra obtained for free 15N-labelled IBD and 15N-labelled IBD in complex with either JPO21–130 or PogZ1117–1410 reveal significant shifts in the positions of backbone amide signals in both complexes (Fig. 3a,b). To interpret the changes in the IBD signal positions, we acquired essentially complete sequence-specific backbone resonance assignment of 13C/15N-labelled IBD using a set of standard triple-resonance NMR experiments. We assigned 95.4% of 1H, 15N, 13C′ and 13Cα/β atoms of the IBD. Backbone amide signals (15N and 1H) were assigned for all residues except for four amino acids (E345, M348, Q410 and T417). There were no unassigned resolved spin systems detected in the spectra.
Formation of the IBD-JPO21–130 and IBD-PogZ1117–1410 complexes was followed via chemical shift perturbations of IBD backbone signals (1H, 15N and 13C′) induced by each binding partner in the 3D HNCO spectra. The specific changes induced by JPO21–130 and PogZ1117–1410 overlapped significantly and were localized in two distinct regions in the IBD sequence (Fig. 3c). In particular, binding of JPO21–130 induced substantial changes in two regions of the IBD structure (residues I359–D369 and K402–M413) including two adjacent, surface-exposed interhelical loops (Fig. 3d). In addition, we identified a subset of residues within those two regions that showed the largest perturbations (N361, L363, K364, D366, L368, D369, I403, R404 and V408). These residues are most likely in direct contact with JPO21–130 (Fig. 3d). We found no evidence of structural changes induced by the binding of JPO21–130 in other parts of the IBD. Similarly, substantial changes in the positions of IBD backbone signals induced by PogZ1117–1410 binding were localized in regions spanning residues K360–D369 and K402–I412. The residues most affected by PogZ1117–1410 binding (N361, L363, K364, L368, D369, I403 and V408) were analogous to those contributing to JPO21–130 binding (Fig. 3d). Highly similar results were obtained previously for mapping of the IBD-MLL1 interaction14, indicating that JPO2, PogZ and MLL1 share a common interaction interface on IBD (Supplementary Fig. 3d).
A linear consensus motif mediates the interaction with IBD
Detailed mapping of the IBD-binding epitopes of JPO2 and PogZ was performed analogously to that of the IBD. Overlays of the 2D 15N/1H HSQC NMR spectra obtained for free 15N-labelled JPO21–130 and PogZ1117–1410 and those measured in complex with IBD revealed significant shifts in the backbone amide signal positions (Fig. 4a,b). Interestingly, the changes observed in the PogZ1117–1410 spectrum were strictly limited to a subset of more intensive signals expected to represent the flexible unstructured C-terminal region of the protein. To gain further insight into the topology of these specific changes, we carried out sequence-specific backbone resonance assignment of 13C/15N-labelled JPO21–130 and PogZ1117–1410 using a set of standard triple-resonance NMR experiments. We assigned 94.4% of 1H, 15N, 13C′ and 13Cα/β atoms of JPO21–130. For PogZ1117–1410, we were able to assign essentially all 1H, 15N, 13C′ and 13Cα/β signals of an apparently unstructured C-terminal region (residues 1,368–1,410) that was significantly affected by IBD binding.
The effects of complex formation on individual amino-acid residues of JPO21–130 and PogZ1117–1410 were quantified as minimal chemical shift values in backbone resonances (15N, 13C′ and 1HN) divided by corresponding s.d. (Fig. 4c,d). In the highly overlapping spectra of the unstructured JPO21–130, we were able to discern seven significantly affected residues (V27, G28, F29, T66, G86, F87 and N93). In the case of PogZ1117–1410, the most affected residues (F1397, Y1398, G1399, F1400 and A1403) were recognized in a single stretch at the C-terminus.
Alignment of the sequences encompassing these residues with the recently published IBD-interacting residues of MLL1 (residues 140–155)14 revealed a conserved consensus sequence ((E/D)-X-E-X-F-X-G-F), which we refer to as the IBM (Fig. 4e). Interestingly, JPO2 contains two of these motifs, IBM-1 (D22-F29) and IBM-2 (E80-F87), while both MLL1 (E144-F151) and PogZ (E1393-F1400) contain only one. Two phenylalanine residues in the IBM of MLL1 have been shown to play a key role in binding to LEDGF/p75; residues F148 and F151 anchor a MLL1-derived peptide in two hydrophobic pockets on the IBD surface in a model of the MLL1/menin-IBD complex (Fig. 4f), and their mutation abrogates the interaction with LEDGF/p75 (ref. 14).
We introduced a F1397A point mutation (PogZF1397A) or a double F1397A/F1400A mutation (PogZF1397A/F1400A) into recombinant maltose binding protein (MBP)-tagged PogZ1117–1410 and evaluated the interactions of these mutants with Flag-tagged LEDGF/p75 in an AlphaScreen assay (Fig. 4g). These mutations abolished the interaction of the PogZ fragment with LEDGF/p75.
Corresponding single and double mutations were introduced in both IBMs of MBP-tagged JPO2 (IBM-1: JPO2F26A and JPO2F26A/F29A; IBM-2: JPO2F84A and JPO2F84A/F87A) and analysed for their interactions with Flag-LEDGF/p75 (Fig. 4h,i). Although these mutations affected the interaction with Flag-LEDGF/p75, they were not sufficient to fully disrupt it. This suggests that both IBM-1 and IBM-2 contribute to the interaction of JPO2 with LEDGF/p75. Mutations of phenylalanines in both motifs (JPO2F26A/F84A or JPO2F26A/F29A/F84A/F87A) fully abolished the interaction of JPO2 with LEDGF/p75 (Fig. 4j). The fact that mutation of phenylalanine residues in the IBM is sufficient to abrogate the interaction is in agreement with previous data obtained for MLL1 (ref. 14). The glycine at position seven in the IBM is most likely conserved owing to its ability to reduce steric hindrance. However, the reason for conservation of the glutamic/aspartic acid residues in positions one and three is less clear. An interaction between this part of the consensus motif and the IBD was not detected in the NMR experiments with JPO2, PogZ (Fig. 4) or MLL1 (ref. 14). To assess the importance of these residues in LEDGF/p75 interactions, we mutated them to alanines. While PogZE1393A/E1395A did not interact with LEDGF/p75 (Fig. 4g), single IBM mutations in JPO2 (JPO2D22A/E24A or JPO2E80A/E82A) disrupted the interaction only partially (Fig. 4h,i). Combining mutations in both IBMs of JPO2 (JPO2D22A/E24A/E80A/E82A) reduced the interaction further, supporting the notion that both JPO2 IBMs can bind LEDGF/p75 (Fig. 4j). The introduced mutations and their effects on LEDGF/p75 binding are summarized in Supplementary Table 1. Taken together, these results establish the existence of an unstructured conserved protein motif responsible for interaction with the LEDGF/p75 IBD.
Structural validation of the consensus motif
To provide a more detailed insight into the actual organization of the interaction interface, initially mapped by backbone NMR signal perturbations, we solved the solution structure of the PogZ-derived peptide in complex with the IBD (PDB ID: 2n3a), as a representative of the IBM. In particular, we determined the solution structure of the PogZ-derived peptide (PogZ1389–1404) in complex with the IBD using the previously published approach14. Comprehensive backbone and side-chain resonance assignments for the PogZ1389–1404 bound 13C/15N labelled LEDGF/p75 IBD were obtained using established triple-resonance experiments and for the bound unlabelled PogZ1389–1404 peptide using 13C/15N filtered homonuclear total correlation spectroscopy and nuclear Overhauser enhancement spectroscopy (NOESY) experiments. The essentially complete 15N, 13C and 1H resonance assignments allowed automated assignment of the nuclear Overhauser effects (NOEs) identified in 3D 15N/1H NOESY-HSQC, 13C/1H HSQC-NOESY and in 2D 13C/15N-filtered/edited NOESY spectra using the protocol implemented in Cyana. This yielded unique assignments for 94.9% (1878/1978) of the NOE peaks observed, providing 1,018 non-redundant 1H–1H distance constraints, including 35 intermolecular constraints (Fig. 4k). Forty converged structures for the IBD-PogZ1389–1404 complex with no distance violations >0.2 Å were obtained from 100 random starting conformations using 1,156 NMR-derived structural constraints (∼13.6 constraints per restrained residue). The 29 lowest energy conformers were further refined in explicit solvent in YASARA (Fig. 4l). Structural statistics for the final water-refined set of structures are shown in Supplementary Table 2.
Analogously to our recently published work on the MLL-LEDGF/p75 interaction14, detailed analysis of the NOESY data revealed that the interaction of PogZ1389–1404 with the IBD is maintained mainly by the aromatic side chains of two phenylalanine residues (F1397 and F1400) within the linear IBM (Fig. 4m). As expected, the IBD adopts a well-defined conformation, while PogZ1389–1404 remains relatively unstructured. PogZ1389–1404 is anchored between the two interhelical loops of IBD (aa I359 to D369 and K402 to M413) via F1397 and F1400 in a similar manner as MLL1140–160, as illustrated by a comparison of the structural data obtained for both complexes shown in Fig. 4m.
IWS1 is a novel interacting partner of LEDGF/p75
Next, we used the ScanProsite40 algorithm to identify additional proteins containing the IBM sequence. In addition to MLL1, JPO2 and PogZ, we found the motif in the known LEDGF/p75 interaction partners MLL2 (ref. 41) and ASK (DBF4) from the CDC7-ASK complex32. Moreover, IBM and IBM-like motifs were found in the mediator complex subunit 1 (Med1; residues 891–898) and IWS1 (residues 484–491; Fig. 5a,b). Three other IBM-containing proteins: eukaryotic translation initiation factor 4H (eiF4H), ATP-binding cassette transporter 1 (ABCA1) and retinitis pigmentosa 1 protein (RP1) were excluded from further studies based on their structures, extranuclear localization and physiological roles.
IWS1 forms a complex with transcription elongation factor SPT6 and the C-terminal domain (CTD) of the large subunit of RNA polymerase II (RNAPII). This complex recruits HYPB/Setd2 histone methyltransferase, which controls H3K36me3 methylation, affecting co-transcriptional pre-mRNA splicing and export42,43. Because LEDGF is linked to both alternative splicing and interaction with H3K36me3, we chose to experimentally investigate the interaction between LEDGF/p75 and IWS1.
We evaluated the binding of recombinant His-tagged full-length IWS1 (His-IWS1) to various GST-tagged LEDGF deletion mutants using AlphaScreen. His-IWS1 interacted exclusively with LEDGF/p75 fragments containing the IBD (full-length GST-LEDGF/p75, GST-LEDGF/p75325–530 and GST-IBD; (Figs 1 and 5c). The interaction between IWS1 and LEDGF/p75 was corroborated by results from a pull-down experiment. GST-tagged LEDGF/p75, LEDGF/p52, PWWP or IBD were immobilized on glutathione sepharose resin and incubated with nuclear extracts of SupT1 cells. IWS1 could only be pulled down by GST-LEDGF/p75 and GST-IBD (Fig. 5d).
To obtain additional insight into the IWS1-LEDGF/p75 interaction, we cloned, expressed and purified a fragment of IWS1 containing the predicted IBM and encoding residues 352–548 (IWS1352–548; Fig. 5b). Fragment boundaries were based on computational analyses including domain and repeat profiling and secondary structure, disorder and hydrophobicity predictions. These predictions indicated that IWS1 residues 1–550 are unstructured and contain a highly acidic Glu-rich region (residues 83–509; Supplementary Fig. 4a,b). The unstructured character of the fragment was verified experimentally using CD spectroscopy, DSF and 1D 1H and 2D 15N/1H HSQC NMR spectra (Fig. 5e, Supplementary Figs 2 and 4c,d). Under optimal conditions (25 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.05% BME), the IBD-IWS1352–548 complex could readily be isolated using analytical SEC (Supplementary Fig. 4d), and the affinity of the interaction was determined using ITC (Fig. 5f). We calculated a Kd value of 6.7±2.0 μM and a 1:1 binding stoichiometry (N=0.96).
We followed the formation of the IBD-IWS1352–548 complexes via chemical shift perturbations of the IBD backbone signals (1H, 15N, 13C′; Fig. 5g) in the 3D HNCO spectra, analogous to our experiments with JPO21–130 and PogZ1117–1410. The specific changes induced by IWS1352–548 were localized to residues K360–D369, K402–V408, I412 and M413 of the IBD and overlap with those found for JPO2, PogZ and MLL1 (Fig. 5h). Overall, these experiments unambiguously confirm a novel IBM-mediated interaction between IWS1 and the LEDGF/p75 IBD.
As published earlier, the binding of HIV-1 integrase, JPO2, PogZ and MLL1 to LEDGF/p75 is mutually exclusive14,30,31. Our NMR data confirmed that IWS1 also shares the same interface on the IBD (Fig. 5g,h). Therefore, we evaluated the effect of HIV-1 integrase catalytic core domain (INCCD), JPO21–130, PogZ1117–1410 and MLL1123–160 titration on the LEDGF/p75-IWS1 interaction in an AlphaScreen assay. As shown in Fig. 5i, untagged INCCD, JPO21–130, PogZ1117–1410 and MLL1123–160 efficiently displaced IWS1 from the LEDGF/p75-IWS1 complex. Apparent 50% inhibitory concentrations (IC50) were: 46 nM for INCCD (95% confidence interval (CI) (36; 59)), 184 nM for JPO21–130 (95% CI (153; 221)), 209 nM for PogZ1117–1410 (95% CI (162; 269)) and 848 nM for MLL1123–160 (95% CI (612; 1,175)). As described above, we obtained dissociation constants for the three studied LEDGF/p75 binding partners (JPO21–130 1.6 μM, PogZ1117–1410 1.9 μM and IWS1352–548 6.7 μM) using ITC. The Kd of LEDGF—IN and MLL1—LEDGF interactions were reported earlier and are 10.9 nM and 86.3 μM, respectively14,44. The Kd and IC50 values follow the same trend with INCCD having higher affinity than the physiological binding partners.
HIV IN, JPO2 and PogZ are known to co-localize with LEDGF/p75 on the chromatin of the cell16,30,31,33. To investigate potential LEDGF/p75-IWS1 co-localization, HeLa cells were transfected with a Flag-tagged IWS1 (Flag-IWS1) expression construct and stained for endogenous LEDGF/p75 and the Flag-tag (Supplementary Fig. 5a). As shown before LEDGF/p75 displayed a dense fine speckled distribution in interphase cells and remained attached to chromatin during mitosis. Flag-tagged IWS1 also localized to the nucleus of the cell but showed a more equal distribution compared with endogenous LEDGF/p75 (Supplementary Fig. 5a). Flag-IWS1 did not co-localize extensively with LEDGF/p75 in the interphase and did not bind mitotic chromatin. However, under the same conditions Flag-tagged HIV IN and JPO2 did co-localize extensively with LEDGF/p75 (Supplementary Fig. 6a) consistently with previously published results16,30,31,33. Neither overexpression of eGFP-LEDGF/p75 (Supplementary Fig. 7), or stable knockdown of LEDGF/p75 (95% as determined by Q-RT-PCR; Supplementary Fig. 5a) did alter the cellular distribution of Flag-IWS1. This is in contrast to earlier reports on the LEDGF/p75 interactors JPO2 and HIV IN30,33,45.
During the reviewing process of this manuscript Gérard et al., reported on the interaction between LEDGF/p75 and IWS1 and revealed its role in HIV latency46. IWS1 is known to form a stable complex with the Suppressor of Ty6 (Spt6) and Gerard et al. could confirm the presence of a LEDGF/p75-IWS1-Spt6 triple complex. We confirmed a direct interaction between recombinant His-tagged IWS1 (His-IWS1) and a GST-tagged Spt6 fragment (GST-Spt6194–230) in the absence of LEDGF/p75 in an AlphaScreen assay (Supplementary Fig. 5b)47. In addition, we could observe extensive co-localization between HA-tagged IWS1 and Flag-Spt6 (Supplementary Fig. 6b). Direct interaction between LEDGF/p75 and SPT6 could not be detected by AlphaScreen or pull-down experiments. However, these experiments confirmed the existence of the LEDGF/p75-IWS1-Spt6 ternary complex (Supplementary Fig. 5c,d). Co-expression of Spt6 did not increase the co-localization of Flag-IWS1 with eGFP-LEDGF/p75 in HeLa cells (Supplementary Fig. 6c).
The IBD-IBM interaction is mimicked by lentiviral integrases
Our structural analysis revealed that MLL1, JPO2 and PogZ interact with the same binding site on the IBD through their IBMs. This binding site is formed mainly by residues from two adjacent interhelical loops connecting IBD helices α1-α2 and α4-α5. The actual binding site consists of a basic surface created by positively charged residues (R404, R405, K407; Fig. 6a) and two hydrophobic pockets (I359, K360, L363, L368, T399, K402, I403, F406, K407 and V408). These hydrophobic pockets are occupied by the conserved IBM phenylalanines, represented by MLL1 F148 and F151 (Fig. 6b). Electrostatic complementarity between the basic patch on the IBD and acidic residues of the IBM, represented by E144 and E146 of MLL1, further contributes to binding (Fig. 6a).
Structural comparison of the complexes of the IBD with the IBM of MLL1 (ref. 14) or HIV-2 IN48 shows considerable overlap of both parts of the interface (Fig. 6a,b). One of the hydrophobic pockets on the IBD surface is occupied by W131 from the HIV-2 INCCD (Fig. 6b). The basic surface of LEDGF/75 is recognized by the IN N-terminal domain (NTD). Specifically, acidic residues E6, E10, and E13 from the α1 helix of the HIV-2 IN NTD face positively charged residues K401, K402, R404 and R405 on the IBD α4 helix (Fig. 6b). The IN NTD-LEDGF/p75 interface is necessary for lentiviral integration48. In particular, LEDGF/p75 residues K401, R404 and R405 have a crucial role in HIV infectivity48. Their counterparts, corresponding to E10 and E13 of HIV-2 IN, are conserved among all lentiviral integrases (Fig. 6c).
To further confirm the overlap of the IBD-binding interfaces of HIV-1 IN and other LEDGF/p75 interaction partners, we tested the binding of LEDGF/p75 mutants defective for interaction with MLL1 (ref. 14) to IWS1, PogZ1117–1410 or HIV-1 IN. These mutations included L368A, which was expected to disrupt the hydrophobic interactions with the IBM phenylalanines or HIV IN tryptophan. R404D, R405D and K407D mutations were designed to target the electrostatic interactions. As expected, the L368A LEDGF/p75 mutant displayed reduced interactions with all binding partners (Fig. 6). A similar effect was seen for LEDGF/p75 containing the R404D/R405D double mutation, which is known to affect interaction with HIV-2 IN E10 (Fig. 6). These results underline the importance of these residues for LEDGF/p75 binding to many interaction partners and confirm features of the overlapping interface. On the other hand, LEDGF/p75 K407 contacts negatively charged side chains of MLL1 but does not establish contact with HIV IN14. Indeed, introduction of a K407D mutation negatively affected the interaction of LEDGF/p75 with IWS1 and PogZ1117–1410 but increased its binding to HIV-1 IN (Fig. 6). In addition, the K407D mutation slightly increased the effect of the L386A mutation on His-IWS1 and MBP-PogZ1117–1410 binding (Fig. 6). The PogZ and IWS1 IBMs thus exhibit similar properties as the MLL1 IBM in binding to LEDGF/p75 L368A and K407D14. In conclusion, although the binding mode of HIV IN to the IBD is not identical to that of the cellular binding partners, it uses the same basic surface and one of the hydrophobic pockets.
LEDGF/p75 is a highly conserved protein present in all vertebrates. In addition, a protein harbouring PWWP and IBD-like domains can be found in arthropods and nematodes such as Drosophila melanogaster and Caenorhabditis elegans49. This conservation, together with the perinatal mortality observed in Psip1 knockout mice proves a crucial physiological role for LEDGF/p75 (ref. 3). LEDGF/p75 is tethered to chromatin through its AT-hooks and the PWWP domain, which recognizes H3K36me3 histone marks (Fig. 1)1,50,51. Although LEDGF/p75-dependent chromatin tethering is essential for MLL1 fusion-driven leukaemia and HIV integration, a direct link to H3K36me3 marks has not yet been established. Likewise, the link between H3K36me3 marks and the potential cellular roles of LEDGF/p75 in DNA damage repair and pre-mRNA processing is not clear.
Along with the PWWP domain, the IBD has a key role in the known physiological and pathological functions of LEDGF/p75 by mediating its interactions with various cellular and viral proteins30,31,32,52. Before this work, the interactions of a diverse set of proteins with the IBD were not fully understood, despite their importance to the development of therapies targeting LEDGF/p75 interactions to block MLL fusion-mediated leukaemic transformation and HIV integration53,54.
Our results revealed that JPO2 and PogZ interact with the IBD through an intrinsically unstructured motif also found in MLL1 (ref. 14). Fragments of JPO2 and PogZ formed stable complexes with the IBD with affinities in the low micromolar range (1.6–1.9 μM) as measured by ITC. NMR experiments revealed that the IBD interaction interfaces for JPO21–130 and PogZ1117–1410 are almost identical to the menin-independent MLL1 interface14. These interactions are maintained by two phenylalanine side chains occupying two hydrophobic pockets on the IBD. The first pocket is formed by IBD residues L363, L368, I403, F406, K407 and V408, while the second is formed by I359, K360, L363, T399, K402 and I403. Sequence alignment of the IBD-interacting regions of JPO2, PogZ and MLL1 revealed a consensus IBM ((E/D)-X-E-X-F-X-G-F), which was validated through comprehensive mutational analysis. IBMs were also identified in two other established LEDGF/p75 binding partners (MLL2 and CDC7-ASK)32,52. The consensus motif harbours two phenylalanine residues; the second phenylalanine is preceded by a glycine, most likely to avoid steric hindrance. These features of the IBM and its binding to IBD were validated by structural analysis of a novel IBD-PogZ1389–1404 complex solution structure. Direct comparison of the IBD-PogZ1389–1404 complex with the structure obtained for the MLL1-derived peptide containing the IBM (PDB ID: 2msr14) therefore validates the conservation of the interactions mediated by the IBM (Fig. 4m). Several glutamic and aspartic acid residues precede the F-X-G-F segment of the motif. Although the interaction of these residues with IBD was not directly detected in any of the PogZ, JPO2 or MLL1 NMR experiments, mutagenesis experiments showed their complex-stabilizing effect in AlphaScreen assays. Interestingly, the CDC7-ASK IBM does not have a glutamic or aspartic acid residue at position 3, but it contains a glutamic acid at position 4 (Fig. 5a).
In PogZ, the consensus motif was identified near the C-terminus, spanning residues E1393-F1400 (Fig. 5a). Mutational analysis confirmed that the phenylalanine residues are essential to maintain the interaction with LEDGF/p75. Likewise, mutation of both conserved glutamic acid residues to alanines abrogated the interaction. While PogZ-like proteins can be found in all bilateria, the IBM is apparently only present in bony vertebrates (Supplementary Fig. 8). Surprisingly, JPO2 contains two IBMs encoded by the second and third exon (Fig. 5a). The presence of two IBMs is in agreement with results from our NMR and ITC experiments, which show an IBD: JPO21–130 stoichiometry of 2:1. Mutational analysis revealed that both motifs can interact with full-length LEDGF/p75 and that phenylalanines from both IBMs had to be mutated to abrogate the interaction. In contrast to PogZ, simultaneous mutation of D22, E24, E80 and E82 to alanines was not sufficient to fully abrogate the interaction. As the IBM of PogZ does not contain neighbouring glutamic and aspartic acid residues, E1394 and E1396 mutations have a more dramatic effect on LEDGF/p75 binding. Like LEDGF/p75 and PogZ, JPO2 is also evolutionally conserved among chordates. The presence of both JPO2 IBM motifs, however, seems to be more variable. While most species contain two motifs, Xenopus tropicalis and Gallus gallus have lost both motifs (Supplementary Fig. 8). In each case, the absence of one or both copies of the motif coincides with a loss of the N-terminal portion of JPO2. Overall, the IBMs of LEDGF/p75 cellular interaction partners are conserved among chordates, suggesting important physiological roles for these interactions.
IBM represents a typical example of Short linear motif (SLiM), a conserved amino-acid sequence present in natively disordered parts of the proteins that mediate binding independently of a larger sequence55. SLiMs are responsible for transient protein–protein interactions and owing to their limited intramolecular contacts with their partners, they tend to bind with low affinity. The short length and the disordered character of these regions provide a high level of plasticity, which makes SLiMs suitable elements to tune the functions of various eukaryotic regulatory proteins. On the other hand, such features also allow SLiMs to be imitated by pathogenic organisms. The ability to mimic the physiological interactions carried out via SLiMs is one of the ways employed by pathogens to take advantage of host cell functions and to guarantee their replication56. HIV-1 integrase is one of numerous viral proteins that evolved the ability to bind a cellular protein in a similar way as its cellular binding partners and exploit its physiological function.
PogZ1117–1410 forms dimers in solution as documented by analytical SEC, similar to Mos-1 DNA transposase the closest enzymatically active structural homologue of PogZ31. Together with our ITC stoichiometry results, this suggests the presence of two LEDGF/p75 molecules in the complex. Owing to the presence of two IBMs in JPO2, the JPO2-LEDGF/p75 complex presumably also contains two LEDGF/p75 molecules. A stable tetramer of HIV IN also has been shown to associate with two molecules of LEDGF/p75 (ref. 16). As such, it is tempting to speculate that multiple LEDGF/p75 molecules are needed to form a functional complex. A recent study reporting LEDGF/p75 dimers bound to certain DNA topologies57 supports this hypothesis. In contrast, IWS1, MLL1 and CDC7-ASK dimers have not been described to date. However, some MLL1 fusions induce dimerization of the fusion protein. For these particular fusions, dimerization is required to maintain the transformed state58.
In addition to the known LEDGF/p75 cellular interaction partners, several other human proteins contain IBMs (IWS1, Med1, eiF4H, ABCA1 and RP1). While the IBMs of Med1 and IWS1 are unstructured, as determined by structural predictions and NMR, respectively, the IBMs of other proteins are situated in predicted structured regions. As all the IBMs known so far are located in unstructured regions, we focused on the IWS1 protein. Intrinsically disordered proteins lack 3D structure yet carry out specific biological functions59. Typical intrinsically disordered proteins provide a platform for transient complex interactions between signalling and regulatory proteins. In eukaryotes, these interactions are especially important in transcription and its regulation59,60. IWS1 forms a stable complex with SPT6 and the CTD of the large subunit of RNAPII42. In addition, IWS1 has been shown to recruit HYPB/Setd2, the only histone methyltransferase known to create H3K36me3 marks43. The unstructured character of IWS1 was experimentally verified via comprehensive biophysical characterization. Next, we confirmed the interaction between IWS1 and LEDGF/p75 using various experimental approaches including NMR, ITC, AlphaScreen and pull-down assays. Moreover we showed that HIV-1 integrase, JPO2, PogZ and MLL1 can compete with IWS1-LEDGF/p75 interaction. However, we did not see extensive co-localization of LEDGF/p75 and IWS1 using confocal microscopy. In contrast to JPO2 and HIV integrase, knockdown of LEDGF/p75 also did not alter the IWS1 nuclear distribution. These results indicate that in contrast to integrase and JPO2, other nuclear determinants are dominant over LEDGF/p75 for the nuclear localization of IWS1. In this regard it is known that IWS1 interacts with the CTD of the large subunit of RNAPII complex through Spt6 (ref. 43). During the reviewing process of this manuscript, Gérard et al. published an independent study, which confirmed the existence of a LEDGF/p75-IWS1-Spt6 triple complex that was suggested to have an important function during HIV latency46. The existence of this complex was confirmed in our study.
When HIV enters the cell, integrase must compete with cellular binding partners to interact with LEDGF/p75. While the high affinity of HIV IN for LEDGF/p75 has been documented previously44, our data provide a structure-based explanation. In comparison with the cellular partners, binding to HIV IN buries a considerably larger hydrophobic surface area. In addition to increased solvent exclusion and concomitant larger entropy gain, this larger interface also allows for additional electrostatic and van der Waals interactions to be established. In addition, the binding site on IN is structurally prearranged, in contrast to the unstructured IBM.
Detailed characterization of LEDGF/p75 interaction interfaces is important in light of efforts to develop novel inhibitors to target IBD interactions with MLL1-menin or HIV-1 IN (reviewed in ref. 61 and ref. 54). From our results, it is clear that potential inhibitors targeting the LEDGF/p75 IBD might disturb other physiological interactions. The cyclic peptide inhibitor CP65, for example, has been shown to disrupt the interactions of LEDGF/p75 with JPO2, MLL1 and HIV IN14,62. Although small cyclic peptides bind to the IBD and can inhibit HIV replication and leukaemic transformation in cell lines, their overexpression does not lead to any apparent toxicity. On the other hand, highly selective inhibitors of the HIV-1 IN-IBD interaction, such as LEDGINs54, were developed by targeting the binding partner (that is, HIV IN) rather than LEDGF/p75. However, this strategy might be challenging to apply to the interaction of LEDGF/p75 with MLLN-fusions because the target would be intrinsically unstructured.
In conclusion, our results unambiguously define a common LEDGF/p75 interaction interface shared by JPO2, PogZ, MLL1, IWS1 and HIV IN, which is most likely used by other known LEDGF interaction partners (ASK and MLL2; Fig. 7). We demonstrate that this part of the IBD serves as a recognition interface for an intrinsically disordered consensus motif, whereby LEDGF/p75 can act as a chromatin tethering factor for its binding partners. Use of a single interface for several protein–protein interactions with intrinsically disordered regions is analogous to other transcription regulators such as the kinase-inducible domain interacting (KIX) domain63. HIV has evolved an alternative way to bind this recognition interface and usurp the elegant molecular tethering mechanism of LEDGF/p75 to achieve efficient integration.
Protein expression and purification
Unlabelled IBD, PogZ1117–1410, IWS1352–548 and JPO21–130 proteins were overexpressed from modified pMCSG7 vectors in E. coli BL21 (DE3) cells grown at 30 °C in lysogeny broth (LB) (Sigma) supplemented with 0.8% glycerol and 100 μg ml−1 ampicillin. When cultures reached an OD550 nm of ∼0.8, heterologous expression was induced by addition of isopropyl-β-D-thiogalactopyranoside (IPTG). The IPTG concentration, duration and temperature of cultivation were optimized for individual proteins to achieve maximal protein yields. Optimal conditions were 0.25 mM IPTG, 5 h at 30 °C for JPO2; 0.2 mM IPTG, 4 h at 20 °C for the IBD; 0.25 mM IPTG, 4 h at 30 °C for PogZ1117–1410 and 0.2 mM IPTG, 4 h at 30 °C for IWS1352–548.
Bacterial cells were collected by centrifugation and resuspended in lysis buffer. The lysis buffer for the IBD, IWS1352–548 and PogZ1117–1410 was 25 mM sodium phosphate, pH 7.8, 1 M NaCl, 40 mM imidazole and 0.05% BME. For lysis of JPO21–130, buffer containing 25 mM sodium phosphate, pH 8.0, 1 M NaCl, 15 mM imidazole and 0.05% BME was used. EDTA-free cOmplete protease inhibitor cocktail (Roche) tablets were added to the cell suspensions to block protease activity. Bacterial cells were disrupted by three passages through an Emulsiflex cell disrupter at 30 ksi. The lysate was centrifuged to remove insoluble materials, and the supernatant was used for further purification steps. The supernatant was clarified by filtration through a sterile Millex filter unit (porosity 0.8 μm; Millipore) and subjected to affinity chromatography using a HisTrap HP 5 ml column (GE Healthcare) equilibrated with lysis buffer. The His6-tagged protein was eluted in a gradient of lysis buffer supplemented with 400 mM imidazole, which was then eliminated from the sample by dialysis against lysis buffer without imidazole. The samples were incubated overnight with recombinant His6-tagged tobacco etch virus (TEV) protease at 16 °C to remove the affinity tag. Following TEV cleavage, a second round of His-Select Nickel Affinity Gel affinity chromatography was performed to remove TEV protease and uncleaved His6-tagged protein. The sample was then concentrated using Amicon Ultra Concentrators (Millipore). The final purification step was SEC on a Superdex 200 10/300 GL column using an Äkta Basic FPLC system (Amersham Biosciences) equilibrated in lysis buffer without imidazole.
This purification protocol yielded 16.5 mg of purified IBD and 7.1 mg of purified PogZ1117–1410 per liter of bacterial culture. The final yields of purified JPO21–130 and IWS1352–548 were 5.1 and 9 mg, respectively, per liter of bacterial culture. The identities of purified JPO21–130 and IWS1352–548 were confirmed by intact mass measurements (MALDI-TOF) and peptide mass fingerprinting (LC–MS), as there were irregularities in their gel migration behaviour typical for unstructured proteins (Supplementary Fig. 9).
Flag-tagged LEDGF/p75 and mutants were expressed and purified in the same way as described for non-tagged LEDGF/p75 (ref. 30). Production of wild-type (WT) MBP-JPO2 (ref. 45), MBP-PogZ1117–1410 (ref. 31) and mutants thereof were performed as described earlier.
GST-tagged LEDGF/p75, LEDGF/p52, PWWP, IBD, GST-LEDGF/p75325–530 and GST-tagged Spt6194–230 were expressed in E. coli BL21 grown on LB medium supplemented with 20 μg ml−1 ampicillin. Bacterial cultures were grown at 37 °C. Protein expression was induced with 1 mM IPTG at an OD600 nm of 0.6. Cultures were harvested after 4 h. Pellets were washed in 20 ml STE buffer (10 mM Tris-HCl, pH 7.3, 100 mM NaCl, 0.1 mM EDTA), and stored at −20 °C. Cells were lysed in buffer containing 50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM dithiothreitol (DTT), 0.1 μg ml−1 DNAse (Thermo Scientific) and protease inhibitor (cOmplete, EDTA-free, Roche). Purification was carried out by affinity chromatography on Glutathione Sepharose-4 Fast Flow (GE Healthcare, Fairfield, CT, USA). The resin was equilibrated with wash buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM DTT), and GST-tagged proteins were eluted in wash buffer supplemented with 20 mM glutathione. The fractions were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for protein content. Peak fractions were pooled and dialysed against 50 mM Tris-HCl, pH 7.5, 250 mM NaCl and 10% (v/v) glycerol.
Full-length His-IWS1 was expressed in E. coli BL21 (DE3) at 30 °C. Protein expression was induced with 0.2 mM IPTG at an OD600 nm of 0.8, and the culture was harvested after 3 h. Cells were washed in 20 ml STE buffer (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1 mM EDTA). Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl, 20 mM imidazole, 0.1 μg ml−1 DNAse (Thermo Scientific) and protease inhibitor (cOmplete, EDTA-free, Roche)) and lysed by sonication. The lysate was cleared by centrifugation at 19,800g for 30 min at 4 °C and subjected to affinity chromatography using His-Select Nickel Affinity Gel (Sigma) equilibrated with wash buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM imidazole). His-tagged proteins were eluted with wash buffer containing 250 mM imidazole. Fractions were analysed by SDS-PAGE for protein content. Peak fractions were dialyzed against a 100-fold excess of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% (v/v) glycerol at 4 °C overnight.
Uniformly 15N- and 15N/13C-labelled IBD, PogZ1117–1410 and JPO21–130 were produced from cells grown in minimal media containing 15N-ammonium sulfate and 13C-D-glucose as the sole nitrogen and carbon sources. The media were supplemented with 20 μg ml−1 ampicillin, and cells were grown at 30 °C for 6 h before being transferred to 20 °C. After temperature stabilization, heterologous expression was induced by addition of IPTG. The final concentration of IPTG for both IBD and JPO21–130 expression was 0.2 mM with cultivation for 15 h at 20 °C; for PogZ1117–1410 we used 0.2 mM IPTG, 16 h at 20 °C and for IWS1352–548 0.2 mM IPTG, 14 h at 18 °C. The purification protocol for labelled proteins was the same as for the corresponding recombinant protein fragments expressed by cells grown in LB medium.
Far-ultraviolet CD spectroscopy experiments were carried out using a Jasco 815 spectrometer at 20 °C. The buffer contained 10 mM sodium phosphate, pH 8.0, and 100 mM NaCl, with final protein concentrations of 0.125 mg ml−1. The CD spectra were recorded from 190 to 300 nm in a 0.1 cm quartz cell. After baseline correction, the spectra were converted to molar ellipticity θ (deg cm2 dmol−1) per residue, and the α-helical fractions were calculated.
Analytical SEC was performed using the Äkta Basic FPLC system (Amersham Biosciences) on a Superdex 200 10/300 GL Tricorn column (Pharmacia). The column was equilibrated with buffer containing 50 mM Tris-HCl, pH 7.8, 150 mM NaCl and 0.05% β-mercaptoethanol. The protein standards (Sigma-Aldrich) used for molecular weight estimation were blue dextran (2,000 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), cytochrome c (12.4 kDa) and aprotinin (6.5 kDa).
Differential scanning fluorimetry
DSF analysis using a real-time PCR LightCycler 480 II (Roche) was performed to assess the stabilizing effects of various buffers and their effects on complex formation. Sixteen buffers (100 mM) covering the near neutral pH range were tested in the presence or absence of 200 mM NaCl as described by Ericsson et al.64. Proteins (0.1 mg ml−1) were assayed in the presence of 8 × Sypro Orange dye (Invitrogen) in a total reaction volume of 25 μl. The plates were sealed with LightCycler 480 Sealing Foil (Roche), and a temperature gradient from 20 to 95 °C with a rate of 1 °C min−1 was applied. The fluorescence intensity of Sypro Orange was recorded at 580 nm, with an excitation wavelength of 465 nm. All experiments were performed at least in duplicate.
Isothermal titration calorimetry
ITC experiments were performed using a MicroCal Auto-iTC200 System (GE Healthcare) at 25 °C. The samples were prepared in 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 0.05% BME. Protein concentrations were determined by amino-acid analysis. For the IBD-JPO21–130 complex, 2 μl aliquots of 60 μM JPO21–130 were injected stepwise into a sample cell containing 200 μl of 10 μM IBD. For the IBD-PogZ1117–1410 complex, 2 μl aliquots of 114 μM PogZ1117–1410 were injected stepwise into a sample cell containing 200 μl of 10 μM IBD. The samples for IWS1 titration experiments were prepared in 50 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.05% BME. For the IBD-IWS1352–548 complex, 2 μl aliquots of 145 μM IWS1352–548 were injected stepwise into a sample cell containing 200 μl of 15 μM IBD. Each assay was accompanied by a control experiment in which the binding buffer was titrated with the injected protein alone. All experiments were performed at least in triplicate. The association constants and stoichiometry (N) were estimated using MicroCal Origin software (GE Healthcare). Known variances of each measurement were used to calculate the weighted average of the dissociation constant (Kd) and stoichiometry as a maximum likelihood estimator.
NMR spectra were acquired at 25 °C on a 600 MHz Bruker Avance spectrometer equipped with triple-resonance (15N/13C/1H) cryoprobe. The sample volume was 0.35 ml, with protein concentrations ranging from 0.1 mM to 0.35 mM for free JPO21–130, IBD, IWS1352–548 and PogZ1117–1410 proteins as well as IBD-JPO21–130, IBD-IWS1352–548 and IBD-PogZ1117–1410 complexes in 25 mM HEPES, pH 7.0, containing 100 mM NaCl, 0.05% BME, 5% D2O/95% H2O. A series of double- and triple-resonance spectra were recorded to determine essentially complete sequence-specific resonance backbone assignments for the free IBD and backbone and side-chain assignments for the PogZ1389–1404 bound IBD, as previously described65,66. The specific interactions of PogZ1117–1410, IWS1352–548 or JPO21–130 with IBD were monitored by changes in the positions of signals of 15N/13C-labelled IBD in 3D HNCO spectra. From these changes, the most affected amino-acid residues were determined using the minimal backbone chemical shift (15N, 13C′ and 1HN) approach67. Amino-acid residues within these regions that were perturbed at least 1.5-fold the s.d. were then mapped on the structure of the IBD in complex with HIV IN (PDB ID 2B4J38). The assignments for the bound PogZ1389–1404 peptide were obtained using 13C/15N filtered homonuclear total correlation spectroscopy and NOESY experiments. 1H–1H distance constraints required to calculate the structure of the IBD-PogZ1389–1404 complex were derived from 3D 15N/1H NOESY-HSQC, 13C/1H HSQC-NOESY and in 2D 13C/15N-filtered/edited NOESY spectra, which were acquired using NOE mixing time of 120 ms. The family of converged structures for the IBD-PogZ1389–1404 complex was initially calculated using Cyana 2.1. The combined automated NOE assignment and structure determination protocol68 was used to automatically assign the NOE cross-peaks identified in NOESY spectra and to produce preliminary structures. In addition, backbone torsion angle constraints, generated from assigned chemical shifts using the program TALOS+69 were included in the calculations. Subsequently, five cycles of simulated annealing combined with redundant dihedral angle constraints were used to produce the sets of converged structures with no significant restraint violations (distance and van der Waals violations <0.2 Å), which were further refined in explicit solvent in YASARA (http://www.yasara.org/). Analysis and validation of the family of structures obtained was carried out using the programs Molmol, iCING and PyMol.
A 40 μl aliquot of 10 μM GST-LEDGF/p75, GST-LEDGF/p75325–530, GST-IBD, GST-PWWP or GST-LEDGF/p52 was mixed with 40 μl Glutathione Sepharose resin (GE Healthcare) pre-equilibrated with wash buffer (50 mM Tris-HCl, pH 7.3, 200 mM NaCl) and incubated for 2 h at 4 °C. The beads were then washed five times with 600 μl wash buffer. The presence of proteins bound to the resin was confirmed by SDS-PAGE (Fig. 5d).
SupT1 cells (NIH: SupT1 from Dr James Hoxie) nuclear extracts were prepared as described by Cherepanov et al.16. The cells were washed with PBS, harvested and lysed with 700 μl lysis buffer (50 mM Tris/HCl, pH 7.3, 150 mM NaCl, 0.5% (v/v) Triton X-100, 10% glycerol, cOmplete protease inhibitor cocktail (Roche, Germany)) for 10 min on ice. The lysate was cleared by centrifugation to divide nuclear and cytosolic fraction. To isolate the nuclear extract, the pellet was resuspended in 50 mM Tris/HCl, pH 7.3, 400 mM NaCl, 0.5% (v/v) Triton X-100, 10% glycerol, cOmplete protease inhibitor cocktail (Roche, Germany) and incubated for 30 min on ice and subsequently cleared by centrifugation. Extracts were diluted with 50 mM Tris-HCl, pH 7.3, bringing the salt concentration down to 200 mM. The lysate (1 ml) was added to the GST-tagged proteins bound to Glutathione Sepharose and incubated for 3 h at 4 °C. The beads were collected by centrifugation (60 s, 340g, 4 °C) and washed five times in 600 μl lysis buffer. Bound proteins were eluted with 50 μl SDS-PAGE loading buffer and analysed by western blotting for the presence of IWS1 using 1:5,000 anti-IWS1 polyclonal rabbit antibody (Cell Signaling Technology, 5681S). Uncropped and marked scans of western blot and SDS-PAGE gel are available in Supplementary information (Supplementary Fig. 10).
AlphaScreen measurements were performed in a total volume of 25 μl in 384-well Optiwell microtiter plates (PerkinElmer). The optimal protein concentrations for each experiment were determined by cross-titration to avoid binding curve perturbation while still yielding a high signal-to-noise ratio. All components were diluted in assay buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM DTT, 0.1% (v/v) Tween-20 and 0.1% (w/v) bovine serum albumin). For binding curve determinations, MBP-JPO2 and MBP-PogZ1117–1410 WT and/or mutants were titrated against 200 nM Flag-LEDGF/p75. For identification of the IWS1 interaction site on LEDGF, GST-LEDGF/p75, GST-LEDGF/p52, GST-PWWP, GST-LEDGF/p75325–530 and GST-IBD were titrated against 20 nM His-IWS1. To assess the interaction effects of LEDGF/p75 mutants, WT or mutant LEDGF/p75 was titrated against 20 nM His-HIV-1 IN or His-IWS1 or 1 nM MPB-PogZ or MBP-JPO2. Plates were incubated for 1 h at 4 °C. Subsequently, a mix of AlphaScreen donor and acceptor beads (PerkinElmer) was added (final concentration 20 μg ml−1), bringing all proteins to the indicated final concentrations. After 1 h of incubation at 20 °C, the plate was analysed in an EnVision Multi-label Reader in AlphaScreen mode (PerkinElmer). Each titration was performed in duplicate, and assays were independently repeated three times. Results were analysed in Prism 5.0 (GraphPad software) after non-linear regression with the appropriate equations. One-site specific binding, taking ligand depletion into account, was used for the apparent Kd measurements.
How to cite this article: Tesina, P. et al. Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif. Nat. Commun. 6:7968 doi: 10.1038/ncomms8968 (2015).
Protein Data Bank
We would like to thank Milan Kozisek, Lucie Bednarova and Radko Soucek (IOCB AS CR) for their help with collecting, processing and analysing ITC and CD data and with amino-acid analysis. We also thank Martine Michiels for excellent technical assistance. This work was supported by a grant from the FP7 framework of the European Union (THINC, HEALTH-2007-2.3.2-1); the Ministry of Education of the Czech Republic—LK11205 (programme ‘NAVRAT’), 7E08066, LO1304 (programme ‘NPU I’) and Project InterBioMed LO1302; the Academy of Sciences of the Czech Republic, projects RVO 61388963 and 68378050 and Charles University in Prague, project GA UK 200213 and SVV-2015-260209. The Research Foundation Flanders, G.0595.13 and KAN2012 22.214.171.124; the Flemish agency for Innovation by Science and Technology (IWT) SBO Interactomics, QPG-345523; the IAP BelVir and the KU Leuven research fund, IDO/12/008, also provided support.
Supplementary Figures 1-10, Supplementary Tables 1-2, Supplementary Methods and Supplementary References